145 related articles for article (PubMed ID: 38574863)
21. Antiplatelet agents for the treatment of deep venous thrombosis.
Flumignan CD; Nakano LC; Baptista-Silva JC; Flumignan RL
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012369. PubMed ID: 35876829
[TBL] [Abstract][Full Text] [Related]
22. Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review.
Hanna KS; Kaur H; Alazzeh MS; Thandavaram A; Channar A; Purohit A; Shrestha B; Patel D; Shah H; Mohammed L
Cureus; 2022 Aug; 14(8):e28162. PubMed ID: 36148204
[TBL] [Abstract][Full Text] [Related]
23. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
24. Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis.
Lei W; Xie M; Jiang Q; Xu N; Li P; Liang A; Young KH; Qian W
Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359816
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.
Xiang X; He Q; Ou Y; Wang W; Wu Y
Front Pharmacol; 2020; 11():544754. PubMed ID: 33343342
[No Abstract] [Full Text] [Related]
26. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.
Fergusson NJ; Adeel K; Kekre N; Atkins H; Hay KA
Front Immunol; 2023; 14():1178403. PubMed ID: 37180149
[TBL] [Abstract][Full Text] [Related]
27. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
28. Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma.
Sun Z; Liu M
Cytotherapy; 2022 Sep; 24(9):940-953. PubMed ID: 35568624
[TBL] [Abstract][Full Text] [Related]
29. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy.
Johnsrud A; Craig J; Baird J; Spiegel J; Muffly L; Zehnder J; Tamaresis J; Negrin R; Johnston L; Arai S; Shizuru J; Lowsky R; Meyer E; Weng WK; Shiraz P; Rezvani A; Latchford T; Mackall C; Miklos D; Frank M; Sidana S
Blood Adv; 2021 Nov; 5(21):4465-4475. PubMed ID: 34521106
[TBL] [Abstract][Full Text] [Related]
30. Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
Zinzi A; Gaio M; Liguori V; Cagnotta C; Paolino D; Paolisso G; Castaldo G; Nicoletti GF; Rossi F; Capuano A; Rafaniello C
Pharmacol Res; 2023 Apr; 190():106742. PubMed ID: 36963592
[TBL] [Abstract][Full Text] [Related]
31. Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: A systematic review and meta-analysis.
Wang TF; Carrier M; Carney BJ; Kimpton M; Delluc A
Thromb Res; 2023 Jul; 227():8-16. PubMed ID: 37196605
[TBL] [Abstract][Full Text] [Related]
32. The risk factors for coagulation disorder of chimeric antigen receptor-T cell therapy in patients with hematological tumors: A systematic review and meta-analysis.
Xia Y; Tang L; Hu Y
Technol Health Care; 2023; 31(6):2363-2380. PubMed ID: 37545264
[TBL] [Abstract][Full Text] [Related]
33. Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: A systematic scoping review and narrative synthesis.
Reynolds G; Sim B; Anderson MA; Spelman T; Teh BW; Slavin MA; Thursky KA
Clin Microbiol Infect; 2023 Oct; 29(10):1280-1288. PubMed ID: 37201866
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia.
Tan Y; Shan L; Zhao L; Deng B; Ling Z; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Tian Z; Zhang Y; Zhang J; Chang AH; Feng X; Pan J
J Hematol Oncol; 2023 Apr; 16(1):34. PubMed ID: 37020231
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis.
Chen LR; Li YJ; Zhang Z; Wang P; Zhou T; Qian K; Fan YX; Guo Y; He GH; Shen L
Front Oncol; 2022; 12():924208. PubMed ID: 36439485
[TBL] [Abstract][Full Text] [Related]
36. Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.
Lalu MM; Kekre N; Montroy J; Ghiasi M; Hay K; McComb S; Weeratna R; Atkins H; Hutton B; Yahya A; Masurekar A; Sobh M; Fergusson DA
Syst Rev; 2023 Jan; 12(1):9. PubMed ID: 36653879
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
[TBL] [Abstract][Full Text] [Related]
38. Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis.
Telli Dizman G; Aguado JM; Fernández-Ruiz M
Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1455-1476. PubMed ID: 36148506
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy in the treatment of relapsed and refractory multiple myeloma: a systematic-review and meta-analysis of clinical trials.
Li J; Tang Y; Huang Z
Transl Cancer Res; 2022 Mar; 11(3):569-579. PubMed ID: 35402175
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
